Nov 1: Mumbai-based drug maker Glenmark Pharmaceuticals Ltd on Thursday announced the launch of Nourkrin, a clinically-proven proteoglycan replacement formula for addressing one of the key underlying causes of hair loss in males and females, in Russia.
“Nourkrin Woman and Nourkrin Man will be exclusively marketed in Russia by Glenmark Impex LLC, the Russian subsidiary of Glenmark Pharmaceuticals Ltd, under a licensing agreement with Denmark-headquartered firm Pharma Medico ApS,” it said.
Glenmark had already launched Nourkrin Woman in India in early 2018.
According to the company, Nourkrin contains Marilex, a unique and proprietary scientific formula, rich in specific proteoglycans essential for hair follicle growth.
“We are very happy to launch Nourkrin for both women and men in Russia. It is a much awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia offering patients relief from different types of skin disorders for several decades and Nourkrin will be a great addition to this portfolio,” said Csaba Kantor, Senior Vice President & Head – Asia, Russia & CIS, Glenmark Pharmaceuticals.
“Nourkrin Woman and Nourkrin Man, available as tablets, are an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The product will be available through retail pharmacy chains as well as online pharmacies,” the company added.